Melissa Stephenson, Author at BioTuesdays

Developments

University of Cambridge begins COVID-19 trial with PharmaJet needle-free system

PharmaJet’s needle-free Injection system will be used in a clinical trial to deliver a booster vaccine against COVID-19 virus variants. The vaccine developed by DIOSynVax, a spinoff company supported by the University...

January 18, 2022

Executive Moves

Altamira updates RNA therapeutics program with new CDO, NIH grant

Altamira Therapeutics (NASDAQ:CYTO), in a business update on its development activities in RNA therapeutics, appointed Covadonga Pañeda, Ph.D., as chief development officer for RNA therapeutics, effective in early April...

January 13, 2022

Developments

Absci in research collaboration with Merck

Absci (NASDAQ:ABSI), which uses deep learning AI and synthetic biology to expand the therapeutic potential of proteins, entered a research collaboration with Merck (known as MSD outside the U.S. and Canada), using...

January 7, 2022

Developments

Rencofilstat adopted as non-proprietary name for Hepion’s CRV431

Hepion Pharmaceuticals’ (NASDAQ:HEPA) lead drug candidate for the treatment of non-alcoholic steatohepatitis (NASH) and other liver diseases, CRV431, has been renamed, rencofilstat. The non-proprietary name change was...

January 7, 2022

Developments

Stifel sees possible rebound year for biotech; top picks for 2022

In its biotech outlook, Stifel said that “on heels of weakness and negativity, 2022 may turn out to be a rebound year wherein biotech stocks – particularly decliners despite positive results and/or commercial...

January 5, 2022

Developments

Hepion Pharmaceuticals to present clinical data at NASH-TAG conference

Dr. Todd Hobbs, CMO of Hepion Pharmaceuticals (NASDAQ:HEPA), will present data from the company’s Phase 2 AMBITION study with drug candidate, CRV431, at the NASH-TAG 2022 conference at Park City, Utah on Jan. 8...

January 5, 2022

Developments

Sigyn outlines 2021 achievements; 2022 clinical, corporate outlook

In a letter to shareholders, chairman and CEO, Jim Joyce of Sigyn Therapeutics (OTC:SIGY), said that in the face of a pandemic that paused and shuttered numerous clinical research programs, “we translated our vision for...

January 4, 2022

Developments

PharmaJet partner Zydus Cadila in COVID-19 vaccine expansion with Korean firm

Needle-free injection company PharmaJet’s partner, Zydus Cadila, is partnering with Enzychem Lifesciences to manufacture their COVID-19 plasmid DNA vaccine, ZyCoV-D, in Korea. The plan is to manufacture more than 80...

January 4, 2022

Developments

Altamira updates Bentrio EU roll-out, 510(k), new Asian distribution, COVID-19, allergy testing

Altamira Therapeutics (NASDAQ:CYTO) issued a business update on Bentrio, its nasal spray for protection against airborne viruses and allergens. The company has set up contracts with wholesalers in its lead market of...

December 30, 2021

Developments

FDA clears Hepion IND for CRV431 in treatment of liver cancer

The FDA accepted Hepion Pharmaceuticals’ (NASDAQ:HEPA) IND application for CRV431, a liver-targeting, novel cyclophilin inhibitor, for the treatment of hepatocellular carcinoma (HCC). Liver cancer is the sixth most...

December 21, 2021

Author - Melissa Stephenson

University of Cambridge begins COVID-19 trial with PharmaJet needle-free system

Altamira updates RNA therapeutics program with new CDO, NIH grant

Absci in research collaboration with Merck

Rencofilstat adopted as non-proprietary name for Hepion’s CRV431

Stifel sees possible rebound year for biotech; top picks for 2022

Hepion Pharmaceuticals to present clinical data at NASH-TAG conference

Sigyn outlines 2021 achievements; 2022 clinical, corporate outlook

PharmaJet partner Zydus Cadila in COVID-19 vaccine expansion with Korean firm

Altamira updates Bentrio EU roll-out, 510(k), new Asian distribution, COVID-19, allergy testing

FDA clears Hepion IND for CRV431 in treatment of liver cancer

General

More

Sign up for the BioTuesdays weekly newsletter